louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02349750: Endometrial Scratch Injury in Women With Unexplained Infertility Undergoing IUI
Official title: Endometrial Scratch Injury Induced Higher Pregnancy Rate for Women With Unexplained Infertility Undergoing IUI With Ovarian Stimulation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Unexplained Infertility
Keywords: Endometrial Scratch Injury
Unexplained infertility
intrauterine insemenation
ovulation induction
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2015-01-29
Enrollment: 154
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study included 154 infertile women Patients received 100 mg of oral clomiphene citrate for five days starting on day 3 of the menstrual cycle, followed by daily injection of 150 IU of hMG and when more than two dominant follicles reached a diameter of 17 mm 5,000 IU of hCG was injected intramuscularly. Patients were randomly allocated into two equal groups: Group C received IUI without ESI and Group S had ESI using No.8 neonatal feeding tube and after 24 to 36 hours, IUI was performed. Successful pregnancy was con-firmed by ultrasound and patients had failed trial underwent another trial of IUI for a maximum of three trials.

Detailed description: The study included 154 infertile women with mean duration of infertility of 3.9±0.4 years. Patients received 100 mg of oral clomiphene citrate for five days starting on day 3 of the menstrual cycle, followed by daily injection of 150 IU of hMG and when more than two dominant follicles reached a diameter of 17 mm 5,000 IU of hCG was injected intramuscularly. Patients were randomly allocated into two equal groups: Group C received IUI without ESI and Group S had ESI using No.8 neonatal feeding tube and after 24 to 36 hours, IUI was performed. Successful pregnancy was con-firmed by ultrasound and patients had failed trial underwent another trial of IUI for a maximum of three trials.

Eligibility criteria: Inclusion Criteria:

1. Couple with unexplained infertility and assigned for IUI

Exclusion Criteria:

1. Woman's age of more than 40 years
2. Ovarian cyst detected in the ultrasound examination
3. Uterine lesions such as submucosal leiomyoma
4. A previous diagnosis of moderate to severe pelvic endometriosis
5. Women with body mass index ≥35 kg/m2 o
6. Women with signs of hyperandrogenemia dy

Primary outcomes:
measure: clinical pregnancy
timeFrame: 14 days after IUI
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Kasr Alainy medical school
name: Ahmed M Maged, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00511550: Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors
Official title: Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Keywords: peripheral blood stem cells
filgrastim-mobilized
allogeneic transplantation
Unrelated Donors for allogeneic transplantation
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
First posted: 2007-08-06
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE

Brief summary: Peripheral blood stem cells (PBSCs) collected following stimulation with filgrastim are commonly used for autologous hematopoietic transplants. PBSCs are also now being used for some syngeneic and allogeneic hematopoietic transplants involving HLA-matched sibling donors. However, many issues remain unanswered about the use of PBSCs for allogeneic transplants and the effects of filgrastim on healthy individuals. The purpose of this study is to determine the effectiveness of filgrastim stimulated PBSCs in hematopoietic cell transplants involving unrelated donors and to determine the effects of this donation process on unrelated stem cell donors.

Detailed description: This study establishes and evaluates a system to supply peripheral blood stem cell (PBSC)products for use in unrelated donor hematopoietic stem cell (HSC) transplantation. The protocol describes processes for donor identification, education and evaluation. Procedures for administration and monitoring of the stem cell mobilizing agent filgrastim are included. The study also describes procedures for the collection of PBSC products by leukapheresis and includes provisions for indefinite donor follow-up.

Eligibility criteria: Inclusion Criteria:

-Healthy adults

Exclusion Criteria:

* Pregnancy or uninterruptible breastfeeding.
* Sensitivity to filgrastim or to E. coli-derived recombinant protein products.
* History of autoimmune disorders, including rheumatic disease and thyroid disorders. Exception: As with bone marrow donations, donors with a history of thyroid disease who have undergone successful therapy may be suitable.
* History of deep vein thrombosis or pulmonary embolism.
* Thrombocytopenia \<150 x 10(9)/L (\<150,000/uL) at baseline evaluation.
* Current treatment with lithium. Drug interactions between filgrastim and lithium, which may potentiate the release of neutrophils, have not been full evaluated.
* Positive Hemoglobin-Solubility (e.g. SickleDex or equivalent) test.
* Donors receiving experimental therapy or investigational agents.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: University of California San Francisco Medical Center
state: California
Study officials:
affiliation: University of California, San Francisco
name: Thomas G. Martin, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: National Marrow Donor Program
name: John Miller, M.D.,Ph.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT05647850: Optimization and Clinical Study of Early Prediction Model for Neonatal Acute Respiratory Distress Syndrome
Official title: Optimization and Clinical Study of Early Prediction Model for Neonatal Acute Respiratory Distress Syndrome
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Neonatology
Keywords: Neonatal acute respiratory distress syndrome
Model of prediction
Perinatal factors
Lead sponsor: University-Town Hospital of Chongqing Medical University
Sponsor class: OTHER
First posted: 2022-12-13
Enrollment: 2000
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All infants from a multi-center study in China, will hospitalise between January 1, 2023 and December 31, 2025.

Brief summary: The goal of this observational study is to learn about neonatal acute respiratory distress syndrome in describe participant population. The main question it aims to answer is: using perinatal factors to predict early neonatal acute respiratory distress syndrome and reduce its mortality.

Participants' umbilical cord blood will be collected for testing, but will not receive any intervention.


Eligibility criteria: Inclusion Criteria:

* A newborn born alive

Exclusion Criteria:

* Stillborn newborn
* Respiratory distress syndrome(RDS), transient tachypnoea of the neonate (TTN), or congenital anomalies as a primary current acute respiratory condition
* Hereditary endocrine and metabolic diseases
* Incomplete records

Primary outcomes:
measure: General characteristics of the patients
timeFrame: 2023.1-2025.12
Secondary outcomes:
Other outcomes:
Locations:
city: Chongqing
country: China
facility: University-Town Hospital of Chongqing Medical University
state: Chongqing
city: Chongqing
country: China
facility: Women and Children's Hospital of Chongqing Medical University
state: Chongqing
Study officials:
affiliation: University-Town Hospital of Chongqing Medical University
name: Hui Liu
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06760650: Fluorescein Angiography in Patients With Diabetes and Chronic Kidney Disease
Official title: Fluorescein-Induced Acute Kidney Injury in Patients With Diabetes and Chronic Kidney Disease
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Chronic Kidney Disease Stage 4
Chronic Kidney Disease Stage 3B
Chronic Kidney Disease Stage 5
Diabetes Mellitus
Fluorescein Angiography
Acute Kidney Injury
Keywords: Fluorescein Angiography
Acute kidney injury
Chronic kidney disease
Diabetes
Lead sponsor: Saint-Joseph University
Sponsor class: OTHER
First posted: 2025-01-07
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Our study hypothesizes that fluorescein exposure in diabetic patients with advanced chronic kidney disease results in deterioration of kidney function. It will therefore aim to evaluate the incidence of acute kidney injury induced by fluorescein in diabetic patients with CKD. The objective is to determine the incidence, severity and risk factors associated with this deterioration to improve the care of this specific population.

Detailed description: This study will assess the change in serum creatinine in patients with diabetes and advanced chronic kidney disease, after a fluorescein angiography. This is a before and after study that will include 35 patients from the department of ophtalmology over 6 months with a total follow-up for 3 months.

Eligibility criteria: Inclusion Criteria:

* \>18 years old with type 2 or type 1 diabetes and chronic kidney disease stage 3b to 5 (eGFR\<45 mL/min/1.73 m2)

Exclusion Criteria:

* Patients who do not give their consent
* Patients who are allergic to fluorescein
* Patients who are on dialysis
* Patients who had fever, vomiting, diarrhea or any dehydration 48 hours before the intervention
* Patients who had a treatment modification one week before the intervention

Primary outcomes:
measure: Change in serum creatinine
timeFrame: At day 4
Secondary outcomes:
measure: Long-term change in serum creatinine
timeFrame: 3 months
Other outcomes:
Locations:
city: Beirut
country: Lebanon
facility: Faculty of Medicine, Saint Joseph University of Beirut
Study officials:
affiliation: Faculty of Medicine, Saint Joseph University of Beirut
name: Mabel AOUN, M.D., M.P.H.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01044550: Laparoscopy Versus Clinical Follow up to Detect Diaphragm Injury
Official title: Laparoscopy (to Detect Occult Diaphragm Injury) Versus Clinical and Radiological Follow up to Detect Diaphragm Injury and Herniation, in Patients With Asymptomatic Left Thoracoabdominal Stab Wounds: A Prospective Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diaphragm Injury
Keywords: Diaphragm injury
Herniation
Lead sponsor: University of Cape Town
Sponsor class: OTHER
Collaborators: name: Medical Research Council, South Africa
First posted: 2010-01-08
Enrollment: 66
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Title: A randomized prospective study comparing non operative management with laparoscopic treatment in patients with a diaphragm injury following left thoracoabdominal stab wounds.

Aim of the Study: The aim of this study is to access the clinical outcome of potential occult diaphragm injuries in a group of patients presenting at the Groote Schuur trauma centre with left sided thoracoabdominal stab wounds, if an expectant non operative management course is taken.

Objects of the Study: To obtain the above mentioned aim the study will undertake;

* to do laparoscopy on a group of randomly selected patients with left thoracoabdominal stab wounds to obtain the incidence of occult diaphragm injury.
* to assess the incidence and clinical outcome of delayed diaphragm visceral herniation in the study group.


Eligibility criteria: Inclusion Criteria:

* Hemodynamically stable patients
* Patients with penetrating stab wounds bounded by
* Superiorly the 4th intercostal space
* Lateral the tip of the left scapula
* Inferior by the left costal margin
* Medially by the sternum
* Signed informed consent

Exclusion Criteria:

* Hemodynamically unstable patients
* Previous penetrating injury to the area mentioned under inclusion criteria
* Patients requiring early surgical exploration for injuries other than diaphragm injuries
* If a diaphragm injury is detected on imaging
* A positive pregnancy test

Primary outcomes:
measure: To assess the clinical outcome of potential occult diaphragm injuries in patients presenting at the Groote Schuur trauma centre with left sided thoracoabdominal stab wounds, if an expectant non operative management course is taken.
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Cape Town
country: South Africa
facility: University of Cape Town
state: Western Cape
Study officials:
affiliation: University of Cape Town
name: Pradeep Navsaria, FCS (SA)
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06466850: Mesenchymal Stem Cells Derived Exosomes in Osteoarthritis Patients
Official title: The Efficacy of Allogenic Mesenchymal Stem Cells Derived Exosomes in Osteoarthritis Patients
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Osteoarthritis, Knee
Lead sponsor: Isfahan University of Medical Sciences
Sponsor class: OTHER
First posted: 2024-06-20
Enrollment: 20
Sex: ALL
Minimum age (years): 45
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: Present research focuses on the potential of exosomes, which are small vesicles secreted by mesenchymal stem cells (MSCs), as a therapeutic approach for osteoarthritis (OA).

OA is a degenerative joint disorder characterized by the destruction of cartilage and loss of extracellular matrix. It's associated with pro-inflammatory cytokines and increased expression of matrix metalloproteinase (MMP) and "a disintegrin and metalloproteinase with thrombospondin motifs" (ADAMTS).

MSCs have been explored as a new treatment for OA over the last decade1. It's suggested that the paracrine secretion of trophic factors, in which exosomes play a crucial role, contributes to the mechanism of MSC-based treatment of OA.

Exosomes derived from MSCs may suppress OA development. They carry bioactive molecules of the parental cells, including non-coding RNAs (ncRNAs) and proteins and anti-inflammatory factors. These exosomes have shown a significant impact on the modulation of various physiological behaviors of cells in the joint cavity.

This research provides hope for developing more effective and predictable methods of using MSC-derived exosomes for OA treatment.


Eligibility criteria: Inclusion Criteria:

* Chronic history (for at least 3 months) of knee joint pain
* Body mass index (BMI) between 21.5 and 29.5
* Radiographically documented knee osteoarthritis of grades 1 to 3 (Kellgren-Lawrence (K-L) radiographic classification scale)

Exclusion Criteria:

* Rheumatoid arthritis and other rheumatic diseases
* Varus or valgus more than 10 degrees; lateral subluxation of the patella
* Deformity at the joint levels or adjacent to the knee due to fracture or any other injury
* Complete rupture of the ligament and meniscus leading to laxity or locking
* Serious systemic, oncohematological, autoimmune diseases; history of severe allergy; serious failure of vital organs, inability to walk
* Hyaluronic acid infiltration within the previous six months
* Hemoglobin levels \<10 g/dL;

Primary outcomes:
measure: Western Ontario and McMaster University Osteoarthritis index (WOMAC)
timeFrame: 1, 3, and 6 months. The second injection is repeated in day 90 after first injection.
Secondary outcomes:
Other outcomes:
Locations:
city: Isfahan
country: Iran, Islamic Republic of
facility: Leila Dehghani
Study officials:
affiliation: Isfahan University of Medical Sciences
name: Leila Dehghani, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05105750: A Comparative Study of Indobufen and Aspirin in Patients With Coronary Atherosclerosis
Official title: A Comparative Study on Antiplatelet Efficacy of Indobufen and Aspirin in Patients With Coronary Atherosclerosis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Coronary Atherosclerosis
Keywords: Light Transmittance Aggregometry
Indobufen
Aspirin
Plasma Thromboxane
Urine 11-dehydro thromboxane
Lead sponsor: The First Affiliated Hospital with Nanjing Medical University
Sponsor class: OTHER
First posted: 2021-11-03
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In addition, studies have found that indobufen can inhibit coagulation function in rats. Compared with aspirin, the duration of antiplatelet efficacy of indobufen was shorter, and the platelet function recovered completely 24 hours after drug withdrawal. However, there are few studies on the antiplatelet efficacy of indobufen. The investigators' previous study found that the inhibitory effect of indobufen 100 mg Bid on COX system in atherosclerosis or healthy volunteers was equivalent to that of aspirin 100 mg QD, but the inhibitory effect on platelet COX-1 channel was significantly weaker than that of aspirin 100 mg QD. In view of this, this study intends to investigate the antiplatelet effect of indobufen 200 mg Bid in patients with coronary atherosclerosis by comparing it with conventional-dose aspirin 100 mg QD.


Eligibility criteria: Inclusion Criteria:

1. Clinical diagnosis of coronary atherosclerosis without indications for stent implantation.
2. Age ≥ 18 years, ≤ 65 years
3. Sign informed consent

Exclusion Criteria:

1. A history of asthma or allergic constitution or known allergy to indobufen or aspirin.
2. High risk of bleeding (low hemoglobin 10g / L, history of peptic ulcer disease, fecal occult blood positive or known active bleeding, history of cerebral hemorrhage within 6 months, history of fundus hemorrhage, etc).
3. Creatinine was 1.2 times higher than the upper limit of normal value and ALT was 1.2 times higher than the normal value.
4. History of smoking and alcoholism.
5. History of diabetes.
6. Pregnancy and lactation women.
7. Nonsteroidal anti-inflammatory or other antithrombotic drugs other than indobufen are required.
8. Any other reason may affect the results of this study.

Primary outcomes:
measure: MPA
timeFrame: Within 24 hours after one month of medication
measure: TXB2
timeFrame: Within 1 month after one month of medication
measure: 11-dh-TXB2
timeFrame: Within 1 month after one month of medication
Secondary outcomes:
measure: Adverse Events
timeFrame: Within 1 month after the first medication
Other outcomes:
Locations:
city: Nanjing
country: China
facility: First Affiliated Hospital of Nanjing Medical University
state: Jiangsu
Study officials:
References:
Clinical trial NCT04662450: Evaluation and Management of Parturients' Pain Intensity
Official title: Evaluation and Management of Parturients' Pain Intensity
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Labor Pain
Lead sponsor: Harvard Medical School (HMS and HSDM)
Sponsor class: OTHER
First posted: 2020-12-10
Enrollment: 0
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The primary objective of this study is to examine the effects of Attentional Bias Modification (ABM) on the labor pain in parturients. One-third of the participants will undergo ABM training away from affective pain stimuli. One-third of the participants will undergo ABM training away from sensory pain stimuli. The rest of participants will be the control group.

Detailed description: In recent years, significant attention has been paid to the attentional bias in patients with chronic pain. Studies found that Attentional Bias Modification (ABM) could reduce the pain intensity in participants with chronic pain. The investigator's goal is to evaluate the effects of ABM on labor pain and patient satisfaction with the labor and delivery experience.

Eligibility criteria: Inclusion Criteria:

* Parturients who are at 36 weeks gestation (at time of starting the study)

Exclusion Criteria:

1. Any patient who refuses
2. Patients with impaired decision-making capacity
3. Patients who are blind or extremely visually impaired
4. Patients who cannot understand or read English

Primary outcomes:
measure: Effects of Attentional Bias Modification (ABM) on labor pain
timeFrame: 4 weeks (starting from 36-week gestation)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Harvard Medical School (HMS and HSDM)
name: Jie Zhou, MD, MS, MBA
role: PRINCIPAL_INVESTIGATOR
References:
citation: Todd J, Sharpe L, Colagiuri B. Attentional bias modification and pain: The role of sensory and affective stimuli. Behav Res Ther. 2016 Aug;83:53-61. doi: 10.1016/j.brat.2016.06.002. Epub 2016 Jun 15.
citation: Schoth DE, Georgallis T, Liossi C. Attentional bias modification in people with chronic pain: a proof of concept study. Cogn Behav Ther. 2013;42(3):233-43. doi: 10.1080/16506073.2013.777105. Epub 2013 Jun 4.
citation: Duschek S, Werner NS, Limbert N, Winkelmann A, Montoya P. Attentional bias toward negative information in patients with fibromyalgia syndrome. Pain Med. 2014 Apr;15(4):603-12. doi: 10.1111/pme.12360. Epub 2014 Jan 21.